Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

257 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Polman CH, et al. Ann Neurol. 2005 Dec;58(6):840-6. doi: 10.1002/ana.20703. Ann Neurol. 2005. PMID: 16283615 Review.
[Benign forms of multiple sclerosis].
Edan G, Sabouraud O. Edan G, et al. Rev Prat. 1991 Sep 15;41(20):1904-7. Rev Prat. 1991. PMID: 1925374 Review. French.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O. Edan G, et al. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):112-8. doi: 10.1136/jnnp.62.2.112. J Neurol Neurosurg Psychiatry. 1997. PMID: 9048709 Free PMC article. Clinical Trial.
METHODS: Forty two patients with confirmed multiple sclerosis, selected as having a very active disease on clinical and MRI criteria were randomised to receive either mitoxantrone (20 mg intravenously (IV) monthly) and methylprednisolone (1 g iv monthly) or methylprednisol …
METHODS: Forty two patients with confirmed multiple sclerosis, selected as having a very active disease on clinical and MRI criteria were ra …
A systematic study of oligodendrocyte growth factors as candidates for genetic susceptibility to MS. French Multiple Sclerosis Genetics Group.
Mertens C, Brassat D, Reboul J, Eichenbaum-Voline S, Vuillemin-Azais C, Cournu I, Babron MC, Semana G, Edan G, Clanet M, Clerget-Darpoux F, Baron-Van Evercooren A, Lyon-Caen O, Liblau R, Fontaine B. Mertens C, et al. Neurology. 1998 Sep;51(3):748-53. doi: 10.1212/wnl.51.3.748. Neurology. 1998. PMID: 9748021
Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group.
Brassat D, Azais-Vuillemin C, Yaouanq J, Semana G, Reboul J, Cournu I, Mertens C, Edan G, Lyon-Caen O, Clanet M, Fontaine B. Brassat D, et al. Neurology. 1999 May 12;52(8):1632-6. doi: 10.1212/wnl.52.8.1632. Neurology. 1999. PMID: 10331690
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group. Comi G, et al. Lancet. 2001 May 19;357(9268):1576-82. doi: 10.1016/s0140-6736(00)04725-5. Lancet. 2001. PMID: 11377645 Clinical Trial.
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. McDonald WI, et al. Ann Neurol. 2001 Jul;50(1):121-7. doi: 10.1002/ana.1032. Ann Neurol. 2001. PMID: 11456302
[Treatment of progressive forms of multiple sclerosis].
Edan G. Edan G. Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 2):1008-13. Rev Neurol (Paris). 2001. PMID: 11787331 French.
257 results
Jump to page
Feedback